Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
3.170
+0.200 (+6.73%)
Official Closing Price
Updated: 4:00 PM EDT, May 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
↗
December 26, 2023
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.
Via
Investor's Business Daily
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
December 20, 2023
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
3 Genomics Stocks to Unlock the Future of Medicine
↗
December 19, 2023
Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use.
Via
InvestorPlace
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
↗
December 18, 2023
2024 is going to be a sizzler in the biopharma sector.
Via
The Motley Fool
2 Cathie Wood Stocks That Might Be Smart Buys Right Now
↗
December 17, 2023
These two biotech stocks hold enormous potential.
Via
The Motley Fool
Looking Into Recursion Pharmaceuticals's Recent Short Interest
↗
December 06, 2023
Via
Benzinga
This Stock Could Soar by 120%, According to Wall Street
↗
November 22, 2023
Don't rush to buy shares just yet.
Via
The Motley Fool
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
↗
December 17, 2023
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.
Via
Talk Markets
Topics
Artificial Intelligence
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
↗
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
Via
InvestorPlace
Topics
Artificial Intelligence
Cathie Wood Just Dumped $40 Million of Coinbase Global (COIN) Stock
↗
December 14, 2023
Wood is moving away from fintech and Internet names like COIN stock. She's now favoring genomics and artificial intelligence companies.
Via
InvestorPlace
Topics
Artificial Intelligence
These 9 Micro/Small Cap AI Stocks Continue In Bubble Mode
↗
December 12, 2023
9 micro/small cap AI stocks are still in bubble mode advancing 14.8%, on average, last week. In comparison, the Global X Artificial Intelligence & Technology ETF was only up 0.5% and the iShares...
Via
Talk Markets
Topics
Artificial Intelligence
ETFs
Recursion Pharmaceuticals: Q3 Earnings Insights
↗
November 09, 2023
Via
Benzinga
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
↗
December 11, 2023
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to...
Via
Talk Markets
Topics
Artificial Intelligence
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
↗
December 06, 2023
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.
Via
Talk Markets
Topics
Artificial Intelligence
November Recap: Top 9 Micro/Small Cap AI Stocks Up +53%, On Average
↗
December 03, 2023
The top 9 micro- and small-cap AI stocks advanced by 53%, on average, in November.
Via
Talk Markets
Topics
Artificial Intelligence
Hewlett Packard Enterprise Posts Upbeat Earnings, Joins Foot Locker, NetApp And Other Big Stocks Moving Higher On Wednesday
↗
November 29, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Wednesday. Shares of Hewlett Packard Enterprise Company (NYSE: HPE) moved higher during Wednesday’s session following...
Via
Benzinga
Topics
Stocks
Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.
↗
November 26, 2023
Scaling up means having more power to bring to bear on core activities.
Via
The Motley Fool
Topics
Artificial Intelligence
2024’s Hidden Gems: 7 Small-Caps Set for Explosive Growth
↗
November 23, 2023
Small-cap stocks outperform larger companies on an indexed basis, but finding the best among them individually isn't always easy.
Via
InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
November 22, 2023
The popular growth investor keeps adding to some of her favorite stocks.
Via
The Motley Fool
Cathie Wood Just Made a Big Bet on Recursion Pharmaceuticals Stock. Will It Pay Off?
↗
November 21, 2023
Cathie Wood just gave the company a huge vote of confidence.
Via
The Motley Fool
Unlocking AI investment opportunities in healthcare
November 16, 2023
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock
↗
November 13, 2023
Via
Benzinga
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence
↗
November 09, 2023
We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare.
Via
InvestorPlace
Topics
Artificial Intelligence
Bayer and Recursion Focus Research Collaboration on Oncology
November 09, 2023
Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
November 09, 2023
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
3 Stocks to Buy for Their Proximity to Nvidia
↗
November 08, 2023
Nvidia isn't the only AI stock on the market. These three companies stand to benefit from Nvidia's success while offering diversification.
Via
InvestorPlace
Topics
Artificial Intelligence
Recursion to Participate in Upcoming Investor Conference
November 02, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
The 7 Best Cathie Wood Stocks to Buy Now: November Edition
↗
November 01, 2023
Dive into the dynamic world of Cathie Wood stocks, wagering on the disruptive tech gems shaping tomorrow's investment landscape.
Via
InvestorPlace
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
November 03, 2023
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.
Via
Benzinga
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.